Your browser doesn't support javascript.
loading
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.
Johnston, Stephen R D; Toi, Masakazu; O'Shaughnessy, Joyce; Rastogi, Priya; Campone, Mario; Neven, Patrick; Huang, Chiun-Sheng; Huober, Jens; Jaliffe, Georgina Garnica; Cicin, Irfan; Tolaney, Sara M; Goetz, Matthew P; Rugo, Hope S; Senkus, Elzbieta; Testa, Laura; Del Mastro, Lucia; Shimizu, Chikako; Wei, Ran; Shahir, Ashwin; Munoz, Maria; San Antonio, Belen; André, Valérie; Harbeck, Nadia; Martin, Miguel.
Afiliação
  • Johnston SRD; The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: stephen.johnston@rmh.nhs.uk.
  • Toi M; Kyoto University, Kyoto, Japan.
  • O'Shaughnessy J; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX, USA.
  • Rastogi P; University of Pittsburgh/UPMC, NSABP Foundation, Pittsburgh, PA, USA.
  • Campone M; Institute de Cancérologie de l'Ouest, Centre Rene Cauducheau, Saint-Herblain, Nantes, France.
  • Neven P; Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven, Belgium.
  • Huang CS; National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
  • Huober J; Cantonal Hospital St Gallen, Breast Centre St Gallen, Switzerland.
  • Jaliffe GG; Grupo Medico Camino SC, Mexico City, Mexico.
  • Cicin I; Trakya University Faculty of Medicine, Edirne, Turkey.
  • Tolaney SM; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Goetz MP; Department of Oncology, Mayo Clinic, Rochester, MN, USA.
  • Rugo HS; University of California San Francisco Hellen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
  • Senkus E; Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland.
  • Testa L; Instituto D'Or de Pesquisa e Ensino (IDOR), Sao Paulo, Brazil.
  • Del Mastro L; IRCSS Ospedale Policlinico San Martino, UO Breast Unit, Genoa, Italy; Università di Genova, Department of Internal Medicine and Medical Specialties (DIM), Genoa, Italy.
  • Shimizu C; National Centre for Global Health and Medicine, Tokyo, Japan.
  • Wei R; Eli Lilly and Company, Indianapolis, IN, USA.
  • Shahir A; Loxo@Lilly, Indianapolis, IN, USA.
  • Munoz M; Loxo@Lilly, Indianapolis, IN, USA.
  • San Antonio B; Loxo@Lilly, Indianapolis, IN, USA.
  • André V; Eli Lilly and Company, Indianapolis, IN, USA.
  • Harbeck N; Breast Centre, Department of Gynaecology and Obstetrics, Comprehensive Cancer Centre München, LMU University Hospital, Munich, Germany.
  • Martin M; Hospital General Universitario Gregorio Marañon, Universidad Complutense, CIBERONC, GEICAM, Madrid, Spain.
Lancet Oncol ; 24(1): 77-90, 2023 01.
Article em En | MEDLINE | ID: mdl-36493792
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Clinical_trials / Etiology_studies / Risk_factors_studies Limite: Adolescent / Adult / Female / Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Clinical_trials / Etiology_studies / Risk_factors_studies Limite: Adolescent / Adult / Female / Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article